MX2018011698A - Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos. - Google Patents

Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos.

Info

Publication number
MX2018011698A
MX2018011698A MX2018011698A MX2018011698A MX2018011698A MX 2018011698 A MX2018011698 A MX 2018011698A MX 2018011698 A MX2018011698 A MX 2018011698A MX 2018011698 A MX2018011698 A MX 2018011698A MX 2018011698 A MX2018011698 A MX 2018011698A
Authority
MX
Mexico
Prior art keywords
enzymatic
inhibitors
catalytic
hiv patients
positive hiv
Prior art date
Application number
MX2018011698A
Other languages
English (en)
Inventor
Enrique Espinosa Arciniega Héctor
Original Assignee
Instituto Nac De Enfermedades Respiratorias Ismael Cosio Villegas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Enfermedades Respiratorias Ismael Cosio Villegas filed Critical Instituto Nac De Enfermedades Respiratorias Ismael Cosio Villegas
Priority to MX2018011698A priority Critical patent/MX2018011698A/es
Publication of MX2018011698A publication Critical patent/MX2018011698A/es
Priority to PCT/MX2019/050020 priority patent/WO2020067868A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona el uso de antocianinas inhibidoras de CD38 para la elaboración de un medicamento para el tratamiento de la infección por VIH. Este segundo uso se deriva de la reconceptualización del rol de CD38 como una enzima biológicamente funcional, sustentado mediante ensayos experimentales que muestran como la inhibición catalítica disminuye la muerte de células T CD4 y aumenta la capacidad de éstas de diferenciarse a células de memoria efectoras. Estos efectos soportan funciones homeostáticas cruciales en la regeneración del sistema inmune. Los inhibidores catalíticos provienen de berries, en particular, éstos son la kuromanina, la luteolina y la luteolinidina; o alimentos tradicionales mexicanos, como el maíz azul, y son útiles para inhibir la expresión de CD38 incluso hasta a niveles basales.
MX2018011698A 2018-09-26 2018-09-26 Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos. MX2018011698A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2018011698A MX2018011698A (es) 2018-09-26 2018-09-26 Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos.
PCT/MX2019/050020 WO2020067868A1 (es) 2018-09-26 2019-09-19 Uso de inhibidores enzimáticos de cd38 en pacientes vih positivos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018011698A MX2018011698A (es) 2018-09-26 2018-09-26 Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos.

Publications (1)

Publication Number Publication Date
MX2018011698A true MX2018011698A (es) 2019-08-27

Family

ID=68579287

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011698A MX2018011698A (es) 2018-09-26 2018-09-26 Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos.

Country Status (2)

Country Link
MX (1) MX2018011698A (es)
WO (1) WO2020067868A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344154B1 (en) * 2009-10-21 2016-12-07 Maqui New Life S.A. Compositions that include anthocyanidins and methods of use
AU2012276037A1 (en) * 2011-06-29 2014-02-13 Mayo Foundation For Medical Education And Research Small molecule CD38 inhibitors and methods of using same

Also Published As

Publication number Publication date
WO2020067868A1 (es) 2020-04-02

Similar Documents

Publication Publication Date Title
NZ741028A (en) Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
MX2017007976A (es) Compuestos inhibidores de parg.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
BR112017012402A2 (pt) derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg
MX2013011835A (es) Composiciones nutricionales que incluyen acidos grasos de cadena ramificada para la curacion de heridas.
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX2019006047A (es) Oligosacaridos para generacion de sabor.
PH12021551268A1 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
WO2017147130A3 (en) Direct fed microbial for prevention of shrimp disease
PH12017502112A1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112018014654A2 (pt) cepa inovadora de bactérias probióticas e composições e usos da mesma
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
EP2578590A4 (en) ANTI-INFLAMMATORY COMPOUND WITH ANTI-HUMAN EFFECT AGAINST SEVERAL TYROSIN KINASES AND PHARMACEUTICAL COMPOSITION THEREWITH
PH12018501060A1 (en) Composition for preventing or treating hair loss comprising chemokine (c-x-c motif) ligand 1 (cxcl1) protein
MX2018011698A (es) Uso de inhibidores enzimaticos de cd38 en pacientes vih positivos.